Discussing the Brazilian scientific scenario at ISPOR European Congress
| Nov 4, 2016
Evidências – Kantar Health presented three studies in the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). The event was held in Vienna from October 29 to November 2. ISPOR is one of the most important scientific dissemination channels on pharmacoeconomics and outcomes research.
At the congress, Evidências – Kantar Health presented posters on studies addressing innovative issues. Our research is summarized below.
Clinical trials scenario in Brazil: the profile of sponsors
Identifying the profile of clinical research conducted in Brazil, besides the main partnerships and collaborations developed in the country, was the theme of the poster “Clinical trials scenario in Brazil: study and sponsor profiles,” produced by Guilherme Silva Julian, Eloisa de Sá Moreira and Renato Watanabe Oliveira, of the Clinical Research Department of Evidências - Kantar Health in partnership with Fernando Rezende Francisco and Ana Paula Ruenis, members of the Brazilian Association Representative Organizations of Clinical Research (ABRACRO).
“The study identified the profile of clinical trials in the country according to ABRACRO and ClinicalTrials.gov databases, the main sources responsible for the development of clinical trials in Brazil,” Guilherme Julian says. “Unfortunately, we observed that there are few studies with local initiative (pharmaceutical/ biotechnology industries) in sponsored studies, and the pharmaceutical companies are the main sponsors of national studies. In addition, we should also draw attention to the small number of observational studies in the country, a scenario that should change with the growing interest in real-world data.”
Treatment patterns and clinical profile of patients with advanced or relapsed stomach cancer in Brazil
The poster “Real world treatment patterns in metastatic and/or unresectable gastric cancer patients in Brazil” assessed the patterns of care and clinical profile of Brazilian patients with advanced or relapsed stomach cancer. The study was produced by Guilherme Silva Julian, of the Clinical Research Department of Evidências - Kantar Health, in partnership with Fernando Meton (IOC Institute), Ana Paula Victorino (INCA), Daniel Cubero (CEPHO - FM ABC), Carlos Augusto Beato (Foundation Amaral Carvalho) and a customer in the pharmaceutical industry.
“This retrospective multicenter study was conducted in four Brazilian institutions to assess the standards of care in patients with stomach cancer in Brazil,” Julian says. “The results from the 155 patients included show that standards of care are heterogeneous in Brazil, with schemes based on oxaliplatin and irinotecan as the most frequent in the first- and second-line treatment, respectively. These results can further contribute to the development of new therapeutic strategies and/or guidelines in the country.”
Incorporating new technologies in Brazil - evaluation of all decision reports of CONITEC published online since 2011
Evaluating the reports produced by the National Committee for Health Technology Incorporation on SUS (CONITEC) since 2011 on the decisions on incorporating new technologies was the theme of poster “Health technology assessment in Brazil: metrics from the National Commission for Incorporation of Technologies (CONITEC) reports,” produced by Teresa Lemmer, Alexandra Piedade, Eloisa Moreira, Guilherme Julian and Renato Oliveira, of the Market Access, Projects and Clinical Research department of Evidências - Kantar Health.
The study found that the majority of applications (54%) are submitted by public authorities and that often these reports are forwarded to the committee with incomplete economic analysis. “Most reports by public bodies (78%) did not report complete economic analysis – which is a very high proportion compared with the reports submitted by private entities (5.4%),” Lemmer says. “Still, the approval rate of public entities’ incorporation applications is much higher (73%) than when the submitter is a private entity (10%).
“This shows that even if the CONITEC criteria require the inclusion of complete economic analysis (cost-effectiveness/utility, cost-minimization), in practice, many new technologies are incorporated without this kind of analysis, i.e., it is not clear what criteria in fact guide the incorporation of new technologies in the public healthcare system (SUS),” Lemmer continues. “We identified the need to strengthen the inclusion of complete economic analysis to evaluate the incorporation and also of greater clarity and transparency of the factors that guide decision-making processes.”
ISPOR is one of the most important scientific channels for dissemination of pharmacoeconomics and outcomes research. Besides being a public non-profit organization for educational and scientific purposes, the objective of ISPOR is promoting the science of pharmacoeconomics and the research results, and facilitating the translation of this research into useful information for decision makers in the area of healthcare. The society has more than 6,500 members in 100 countries, and 62 regional chapters with over 4,800 members. ISPOR promotes three annual meetings, conducted in North America, Europe and Latin America or Asia.